Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere’s disease, tourette’s syndrome, attention deficit hyperactivity disorder and addiction

Abstract

Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided. Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction.

What is claimed is: 
     
         1 . A method of treating aural fullness or hearing loss in one or both ears associated with sudden sensorineural hearing loss comprising administering to a human patient in need thereof (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof in an amount of from 0.01 mg to 1500 mg and alleviating the aural fullness or hearing loss in the patient. 
     
     
         2 . The method of  claim 1 , wherein the improvement is provided for more than 6 hours after administration. 
     
     
         3 . The method of  claim 1 , wherein the human patient is administered a composition comprising about 1 mg to 1000 mg of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The method of  claim 1 , wherein the human patient is administered a composition comprising about from 250 mg to 1000 mg of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The method of  claim 1 , wherein the total amount of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof administered to the human patient in a twenty-four hour period is between 1 mg and 500 mg. 
     
     
         6 . The method of  claim 1 , wherein (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered from one to four times a day. 
     
     
         7 . The method of  claim 1 , wherein administering is accomplished via a route selected from the group consisting of oral, buccal, sublingual, rectal, topical, intranasal, vaginal and parenteral. 
     
     
         8 . A method of treating aural fullness or hearing loss in one or both ears associated with sudden sensorineural hearing loss comprising administering to a human patient with sudden sensorineural hearing loss (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof in an amount of from 0.01 mg to 750 mg and alleviating the aural fullness or hearing loss. 
     
     
         9 . The method of treating aural fullness or hearing loss in one or both ears associated with sudden sensorineural hearing loss according to  claim 8 , wherein the human patient is administered from 0.1 mg to 500 mg of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The method of treating aural fullness or hearing loss in one or both ears associated with sudden sensorineural hearing loss according to  claim 8 , wherein the human patient is administered from 0.1 mg to 100 mg of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The method of treating aural fullness or hearing loss in one or both ears associated with sudden sensorineural hearing loss according to  claim 8 , wherein the total amount of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof administered to the human patient in a twenty-four hour period is between 1 mg and 10 mg. 
     
     
         12 . The method of treating aural fullness or hearing loss in one or both ears associated with sudden sensorineural hearing loss according to  claim 8 , wherein (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered from one to four times a day. 
     
     
         13 . The method of treating aural fullness or hearing loss in one or both ears associated with sudden sensorineural hearing loss according to  claim 8 , wherein administering is accomplished via a route selected from the group consisting of oral, buccal, sublingual, rectal, topical, intranasal, vaginal and parenteral.